News & Updates

Monthly dosing of the anti-PCSK9 small binding protein lerodalcibep appears to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease (CVD) or at high risk of atherosclerotic CVD who are unable to achieve target LDL-C levels while receiving maximal tolerated statins alone, according to the phase III LIBERATE-HR trial.

Alcohol consumption contributes to a substantial increase in both systolic (SBP) and diastolic (DBP) blood pressure (BP), regardless of the type of alcoholic drink, reports a study.

In patients with Takotsubo syndrome (TTS), late recovery of left ventricular (LV) function appears to contribute to reduced short- and long-term survival, suggests a study.

Among South Asian adults, a culturally adapted, group-based lifestyle intervention does not appear to result in greater improvements in cardiovascular disease (CVD) risk factors as compared with written health education materials, according to the SAHELI study.

The SCOFF* trial presented at ESC 2024 shows that fasting is not necessary prior to cardiac catheterization procedures requiring conscious sedation.

Treatment with evogliptin falls short of providing protective benefits against calcification of the aortic valve (AV), but longer treatment may be helpful, reports a study.

GMRx2, a novel low-dose single pill containing three antihypertensive drugs – telmisartan, amlodipine, and indapamide – achieves all efficacy endpoints in two pivotal phase III trials presented at ESC 2024.